Table 1. Summary of the literatures on outcomes in CRLM after RFA and MWA.
| Authors | Year | Patients | Modality | Follow-up (months)* | LR rate (%)§ | DFS (months)* | OS (months)* |
|---|---|---|---|---|---|---|---|
| Shady et al. (percutaneous) (46) | 2016 | 162 | RFA | 55 | 48 | 26 (LTPFS) | 36 |
| Leung et al. (42) | 2015 | 140 | MWA | 20.5 | 7.9 | NA | 57 |
| Groeschl et al. (22) | 2014 | 198 | MWA | 19 | 5.2 | 24.5 | 32.1 |
| Aliyev et al. (tumors ≤3 cm) (47) | 2013 | 44 | RFA | 32 | 18 | 25 | 47¶ |
| Kennedy et al. (27) | 2013 | 130 | RFA | 42.2 | 4.3 | 17.4 | 40.4 |
| Martin et al. (9) | 2010 | 50 | MWA | 36 | 6 | 12 | 36 |
| Siperstein et al. (48) | 2007 | 234 | RFA | 24 | 18 | 6 | 24 |
§, LR rate is calculated per lesions; *, follow-up, DFS and OS were reported as median unless otherwise specified; ¶, cancer-specific survival. CRLM, colorectal cancer liver metastasis; RFA, radiofrequency ablation, MWA, microwave ablation; LR, local recurrence; DFS, disease-free survival; OS, overall survival; NR, not reached; LTPFS, local tumor progression free survival; NA, not assessed.